# Nuclide record psma-theranostics-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/roadmaps/psma-theranostics-roadmap/>
  a schema:CreativeWork ;
  nuclide:kind "roadmap" ;
  schema:identifier "psma-theranostics-roadmap" ;
  schema:name "PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha"@en ;
  schema:description "Prostate-specific membrane antigen was found on prostate cancer cells in 1987. It took until 2020-2022 for scans and treatments that target it to reach approval, but once they did, PSMA PET and Pluvicto changed how metastatic prostate cancer is staged and treated, and the same target is now being tried earlier in the disease and with more powerful alpha particles."@en ;
  schema:url <https://nuclide.cc/roadmaps/psma-theranostics-roadmap/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212643Orig1s000Approv.pdf>, <https://investor.lantheus.com/news-releases/news-release-details/lantheus-receives-us-fda-approval-pylarifyr-piflufolastat-f-18>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10159870/>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication> ;
  nuclide:related <https://nuclide.cc/isotopes/f-18/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/in-111/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/technologies/lu177-radioligand-therapy/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:drugs <https://nuclide.cc/drugs/ga68-psma-11/>, <https://nuclide.cc/drugs/pylarify/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/illuccix/>, <https://nuclide.cc/drugs/locametz/>, <https://nuclide.cc/drugs/lu177-psma-it/>, <https://nuclide.cc/drugs/ac225-psma/> ;
  nuclide:trials <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/trials/psmafore/>, <https://nuclide.cc/trials/alphabreak/> ;
  nuclide:people <https://nuclide.cc/people/clemens-kratochwil/>, <https://nuclide.cc/people/uwe-haberkorn/>, <https://nuclide.cc/people/michael-morris/>, <https://nuclide.cc/people/thomas-hope/>, <https://nuclide.cc/people/hofman-michael/> ;
  nuclide:keyPapers <https://nuclide.cc/key-papers/paper-vision-nejm-2021/>, <https://nuclide.cc/key-papers/paper-propsma-hofman-lancet-2020/> .